axitinib,sunitinib,pembrolizumab
merck,pfizer
['sunitinib', 'key,note,42', 'pembro', 'keynote-426', 'key,note,426']
long-term f/u from keynote-426 presented by at #asco23. clear in pfs remains vs sunitinib with long f/u but os curves seem to be heading back toward each other. also interesting that pfs curves cont to drop well beyond 2 yr when pembro was completed. 
Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.